Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $38.95, but opened at $43.66. Zealand Pharma A/S shares last traded at $43.66, with a volume of 175 shares.

Wall Street Analysts Forecast Growth

ZLDPF has been the subject of a number of analyst reports. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company’s fifty day simple moving average is $47.94 and its two-hundred day simple moving average is $58.85. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of 3.24 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.50. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. Equities research analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.